BRICS Diabetes Drugs Market – by Injectables (Insulin, Exenatide), Oral Antidiabetic Drugs (Metformin, Sulfonylureas, Thaizolidinediones, Dipeptidyl Inhibitors, Meglitinides, Alpha Glucosidase Inhibitors, Combination Medications), Geography (Brazil, Russia, India, China, South Africa) Forecast to 2026

Market Scenario

BRICS Diabetes Drugs Market is expected to reach USD 61.59 billion by 2026, from XX billion in 2018 at a CAGR of XX %. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. BRICS Diabetes Drugs Market Diabetes is a chronic disease characterized by high blood sugar level, the main cause of diabetes is improper functioning of the pancreas which secretes insulin. The diabetes Drug market is completely based on the drug used to lower glucose level in the blood, with the help of oral hypoglycemic agents or oral ant hyperglycemic agents to ensure treatment of diabetes Selection of different types of diabetes drug completely depends upon • Nature of the Diabetes • Age • Situation of the Person Various driving factors for diabetes drug market are increased life expectancy, changing lifestyles, and the rising incidence of obesity. While using diabetes drugs and drug infusion devices safety and security precautions are taken by the patient could cause challenges for the growth of the market. Diabetes in Russia is also expected to reach at 21.5 million patients by 2026. India and China have the highest number of diabetes patients in the world due to an increased aging population in these regions. China alone is expected to have more than 73 million diabetes patients by 2026. The rising incidence of diabetes in BRICS is estimated to reach astonishingly at 135 million patients by 2026, or about 37% of the world’s diabetic population. Among BRICS nations Brazil is expected to show lower growth rate due to patent expiry of various diabetes drugs. Eli Lilly and Novo Nordisk are the two smarter organizations in this market that have offered easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Key Highlights: • Opportunity analysis in the BRICS Diabetes Drugs market for the stakeholders and competitive landscape for the market leaders and followers • Competitive developments, key trends, R&D expenditure, expansions, mergers & acquisitions, supply chain analysis, new product launches, In BRICS Diabetes Drugs market • BRICS Diabetes Drugs market divided on the basis of Oral Antidiabetic Drugs, Injectables and Country. • BRICS Diabetes Drugs market analysis and forecast for five major regions Brazil, Russia, India, China, and South Africa. • Market forecasting in terms of value in size of the BRICS Diabetes Drugs market and region wise volumes including Brazil, Russia, India, China, and South Africa. • Strategic micro markets analysis (refer to further segments and sub-segments) with respect to individual growth trends, winning edge imperatives, future prospects, and contribution to the total BRICS Diabetes Drugs market • Company Profiling in strategic perspective of key players in the industry in BRICS Diabetes Drugs market and comprehensively analysis of their core competencies For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered Research Methodology: The objective of the study is to estimate the size of the BRICS Diabetes Drugs market for 2017 and projects its demand till 2026 with quantitative and qualitative analysis of BRICS Diabetes Drugs market. Industry experts have studied various industry journals, directories, have referred information available with various associations to identify, collect information and to put it in articulated format to make useful for all stakeholders in the industry. Primary research has been done and various industry experts and suppliers from worlds wide have given their inputs to make the study more accurate Key players in the value chain for BRICS Diabetes Drugs market from raw material supplier side and service providers are included in reports. Some of them are: • Takeda Pharmaceuticals Company • Shreya Life Sciences Pvt Ltd • Bayer Healthcare Ag • Zydus Cadila Healthcare Ltd • Dr. Reddy's Laboratories Ltd • Boehringer Ingelheim • Glenmark Pharmaceuticals Ltd. • Bristol-Myers Squibb • Sanofi-Aventis • Merck & Co. Inc. • Roche Holding Ltd • Eli Lilly And Company • Aurobindo Pharma Ltd • Novo Nordisk A/S • GlaxoSmithKline Plc Key Target Audience for BRICS Diabetes Drugs Market Report: • Research and Consulting Companies • Healthcare Institutions (Individual Surgeons, Medical Schools, Group Practices, Hospitals, and Governing Bodies) • Diabetes Drugs Market Research Associations • Diabetes drug Manufacturers & Distributors Scope of the BRICS Diabetes Drugs Market report: Research report categorizes the BRICS Diabetes Drugs market based on Oral antidiabetic drugs, Injectables and Country. Market size by value is estimated and forecasted with the revenues of leading companies operating in the

Scope of BRICS Diabetes Drugs market

BRICS Diabetes Drugs Market, by Injectables

• Insulin • Exenatide

BRICS Diabetes Drugs Market, By Oral Antidiabetic Drugs

• Metformin • Sulfonylureas • Thaizolidinediones • Dipeptidyl Inhibitors • Meglitinides • Alpha Glucosidase Inhibitors • Combination Medications

BRICS Diabetes Drugs Market, By Country

• Brazil • Russia • India • China • South Africa

Table of Contents

BRICS Diabetes Drugs Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: BRICS Diabetes Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. BRICS Diabetes Drugs Market Analysis and Forecast 6.1. BRICS Diabetes Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. BRICS Diabetes Drugs Market Analysis and Forecast, by Injectables 7.1. Introduction and Definition 7.2. Key Findings 7.3. BRICS Diabetes Drugs Market Value Share Analysis, by Injectables 7.4. BRICS Diabetes Drugs Market Size (US$ Bn) Forecast, by Injectables 7.5. BRICS Diabetes Drugs Market Analysis, by Injectables 7.6. BRICS Diabetes Drugs Market Attractiveness Analysis, by Injectables 8. BRICS Diabetes Drugs Market Analysis and Forecast, by Oral Antidiabetic Drugs 8.1. Introduction and Definition 8.2. Key Findings 8.3. BRICS Diabetes Drugs Market Value Share Analysis, by Oral Antidiabetic Drugs 8.4. BRICS Diabetes Drugs Market Size (US$ Bn) Forecast, by Oral Antidiabetic Drugs 8.5. BRICS Diabetes Drugs Market Analysis, by Oral Antidiabetic Drugs 8.6. BRICS Diabetes Drugs Market Attractiveness Analysis, by Oral Antidiabetic Drugs 9. BRICS Diabetes Drugs Market Analysis, by Region 9.1. BRICS Diabetes Drugs Market Value Share Analysis, by Region 9.2. BRICS Diabetes Drugs Market Size (US$ Bn) Forecast, by Region 9.3. BRICS Diabetes Drugs Market Attractiveness Analysis, by Region 9.4. BRICS Diabetes Drugs Market Analysis, by Country 9.5. China Diabetes Drugs Market Forecast, by Injectables 9.5.1. Insulin 9.5.2. Exenatide 9.6. China Diabetes Drugs Market Forecast, by Oral Antidiabetic Drugs 9.6.1. Metformin 9.6.2. Sulfonylureas 9.6.3. Thaizolidinediones 9.6.4. Dipeptidyl Inhibitors 9.6.5. Meglitinides 9.6.6. Alpha Glucosidase Inhibitors 9.6.7. Combination Medications 9.7. India Diabetes Drugs Market Forecast, by Injectables 9.7.1. Insulin 9.7.2. Exenatide 9.8. India Diabetes Drugs Market Forecast, by Oral Antidiabetic Drugs 9.8.1. Metformin 9.8.2. Sulfonylureas 9.8.3. Thaizolidinediones 9.8.4. Dipeptidyl Inhibitors 9.8.5. Meglitinides 9.8.6. Alpha Glucosidase Inhibitors 9.8.7. Combination Medications 9.9. South Africa Diabetes Drugs Market Forecast, by Injectables 9.9.1. Insulin 9.9.2. Exenatide 9.10. South Africa Diabetes Drugs Market Forecast, by Oral Antidiabetic Drugs 9.10.1. Metformin 9.10.2. Sulfonylureas 9.10.3. Thaizolidinediones 9.10.4. Dipeptidyl Inhibitors 9.10.5. Meglitinides 9.10.6. Alpha Glucosidase Inhibitors 9.10.7. Combination Medications 9.11. Rest of Middle East & Africa Diabetes Drugs Market Forecast, by Injectables 9.11.1. Insulin 9.11.2. Exenatide 9.12. Rest of Middle East & Africa Diabetes Drugs Market Forecast, by Oral Antidiabetic Drugs 9.12.1. Metformin 9.12.2. Sulfonylureas 9.12.3. Thaizolidinediones 9.12.4. Dipeptidyl Inhibitors 9.12.5. Meglitinides 9.12.6. Alpha Glucosidase Inhibitors 9.12.7. Combination Medications 9.13. Middle East & Africa Diabetes Drugs Market Attractiveness Analysis 9.13.1. By Injectables 9.13.2. By Oral Antidiabetic Drugs 9.14. Brazil Diabetes Drugs Market Forecast, by Injectables 9.14.1. Insulin 9.14.2. Exenatide 9.15. Brazil Diabetes Drugs Market Forecast, by Oral Antidiabetic Drugs 9.15.1. Metformin 9.15.2. Sulfonylureas 9.15.3. Thaizolidinediones 9.15.4. Dipeptidyl Inhibitors 9.15.5. Meglitinides 9.15.6. Alpha Glucosidase Inhibitors 9.15.7. Combination Medications 9.16. Russia Diabetes Drugs Market Forecast, by Injectables 9.16.1. Insulin 9.16.2. Exenatide 9.17. Russia Diabetes Drugs Market Forecast, by Oral Antidiabetic Drugs 9.17.1. Metformin 9.17.2. Sulfonylureas 9.17.3. Thaizolidinediones 9.17.4. Dipeptidyl Inhibitors 9.17.5. Meglitinides 9.17.6. Alpha Glucosidase Inhibitors 9.17.7. Combination Medications 10. Company Profiles 10.1. Market Share Analysis, by Company 10.2. Competition Matrix 10.2.1. Competitive Benchmarking of key players by price, presence, market share, Injectables s and R&D investment 10.2.2. New Oral Antidiabetic Drugs Launches and Oral Antidiabetic Drugs Enhancements 10.2.3. Market Consolidation 10.2.3.1. M&A by Regions, Investment and Injectables s 10.2.3.2. M&A Key Players, Forward Integration and Backward Integration 10.3. Company Profiles: Key Players 10.3.1. Takeda Pharmaceuticals Company. 10.3.1.1. Company Overview 10.3.1.2. Financial Overview 10.3.1.3. Oral Antidiabetic Drugs Portfolio 10.3.1.4. Business Strategy 10.3.1.5. Recent Developments 10.3.1.6. Manufacturing Footprint 10.3.2. Shreya Life Sciences Pvt Ltd 10.3.3. Bayer Healthcare Ag 10.3.4. Zydus Cadila Healthcare Ltd 10.3.5. Dr. Reddy's Laboratories Ltd 10.3.6. Boehringer Ingelheim 10.3.7. Glenmark Pharmaceuticals Ltd. 10.3.8. Bristol-Myers Squibb 10.3.9. Sanofi-Aventis 10.3.10. Merck & Co. Inc. 10.3.11. Roche Holding Ltd 10.3.12. Eli Lilly And Company 10.3.13. Aurobindo Pharma Ltd 10.3.14. Novo Nordisk A/S 10.3.15. GlaxoSmithKline Plc 11. Primary Key Insights

About This Report

Report ID 356
Category Healthcare
Published Date
No of Pages 186
Contact Us